Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tourmaline Bio, Inc. - Common Stock (NQ:TRML)

47.59 -0.05 (-0.09%)
Streaming Delayed Price Updated: 11:30 AM EDT, Sep 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,635,915
Open 47.62
Bid (Size) 47.59 (121)
Ask (Size) 47.60 (173)
Prev. Close 47.64
Today's Range 47.58 - 47.64
52wk Range 11.56 - 47.69
Shares Outstanding 42,166,025
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Wall Street Cheers Nebius-Microsoft Megadeal While Apple Misses the Mark
U.S. markets closed higher on Tuesday, buoyed by fresh labor data signaling a cooling job market—potentially paving the way for Fed rate cuts. Nebius soared nearly 50% on a multibillion-dollar AI-cloud... 
Via Chartmill
Topics Economy
Let's take a look at the stocks that are in motion in today's session.
Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill

Performance

YTD
+130.6%
+130.6%
1 Month
+126.8%
+126.8%
3 Month
+150.5%
+150.5%
6 Month
+197.1%
+197.1%
1 Year
+170.7%
+170.7%

More News

Read More
Dow Surges Over 100 Points; Korn Ferry Earnings Top Views
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Tourmaline Bio Stock Just Rocketed 58% Pre-Market – Here’s What Happened
Via Stocktwits
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRML, WOW, BTBD, WKHS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Tourmaline Bio, Inc. (Nasdaq - TRML), BT Brands, Inc. (Nasdaq - BTBD), WideOpenWest, Inc. (NYSE - WOW), Workhorse Group Inc. (Nasdaq - WKHS)
From Brodsky & Smith LLC
Via GlobeNewswire
Tourmaline Bio, QMMM Holdings, Teck Resources And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense'
Via Investor's Business Daily
Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion
Via Investor's Business Daily
Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Nebius Group Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
Via Benzinga
TRML Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Tourmaline Bio, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Shareholder Alert: The Ademi Firm investigates whether Tourmaline Bio, Inc. is obtaining a Fair Price for its Public Shareholders
From The Ademi Firm
Via Business Wire
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Reports Loss as R&D Rises
Via The Motley Fool
Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill
Trip.com Posts Weak Earnings, Joins Vipshop, Viking Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
From Tourmaline Bio, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Tourmaline Bio, Inc. - Common Stock publicly traded?
Yes, Tourmaline Bio, Inc. - Common Stock is publicly traded.
What exchange does Tourmaline Bio, Inc. - Common Stock trade on?
Tourmaline Bio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tourmaline Bio, Inc. - Common Stock?
The ticker symbol for Tourmaline Bio, Inc. - Common Stock is TRML on the Nasdaq Stock Market
What is the current price of Tourmaline Bio, Inc. - Common Stock?
The current price of Tourmaline Bio, Inc. - Common Stock is 47.59
When was Tourmaline Bio, Inc. - Common Stock last traded?
The last trade of Tourmaline Bio, Inc. - Common Stock was at 09/10/25 11:30 AM ET
What is the market capitalization of Tourmaline Bio, Inc. - Common Stock?
The market capitalization of Tourmaline Bio, Inc. - Common Stock is 2.01B
How many shares of Tourmaline Bio, Inc. - Common Stock are outstanding?
Tourmaline Bio, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.